



# Site Closure Resource Guide for Research Personnel and Principal Investigators

**Purpose:** To provide guidance from data entry to IRB submission and determination letter dissemination.

## Audience: Research Personnel and Principal Investigators

**Summary:** This resource guide will focus on the site closure from data entry to IRB submission and determination letter dissemination. The information provided in this resource guide contains helpful information for both research personnel and principal investigators. Please consult the Table of Contents below to find the information you need.

## Table of Contents:

- Dashboard Information
- <u>Study Profile Information</u>
- <u>Start a Site Closure Form</u>
- Site Closure Data Entry
- Pl Sign-Off and Admin Pre-Review
- IRB Review
  - o Expedited Review
  - o Referral to Full-Board
  - o Full-Board
- Terminology for IRBManager



### **Dashboard Information:**

- 1. When you log into IRBManager, your dashboard will appear. The information on your dashboard can be subdivided into four categories:
  - a) Actions Sidebar: Here, you can start x-forms<sup>1</sup> or go to your recently reviewed items. You can also see the progress status of all your x-forms.
  - b) My Projects Boxes: Under 'My Projects,' you will see more information on your projects<sup>2</sup>, x-forms, and study events<sup>3</sup>.
  - c) Notices Box: Important IRB information can be found here.
  - d) My Projects Table: The table is a listing of all your active research studies. By clicking on the blue study link, you will be directed to the study profile.

Adventist	Home				Find	Proje	ct (Ctrl+Q)	
HealthCare	Ny Projects	5		Ta	ake a tour		elp Test's Sett	ings Sign (
Actions	Projects (	6 Active)			Notices		c) Notices Box	
IRB Member/Consultant/Invit Confidentiality Statement Reliance Agreement	• • You are • • There ar	the PI for <u>6 a</u> re <u>2 studies</u> e	<u>ctive</u> a xpiring	<u>tive</u> Projects and <u>6 total</u> Projects. nd <u>6 total</u> Projects. in the next 90 days. <u>019-TEST-SGMC</u> .		dventis	he IRB Office at (3 sthealthcare.com	
Start xForm Show Sponsor IDs	xForms (1	l0 Active)						
-		e <u>2 unsubmit</u>						
Recent Items 2019-TEST-SGMC	<ul> <li>You have</li> </ul>	e <u>8 xForms</u> b	eing pr	ocessed at a later stage.				
2019-1251-5GMC 2017-07-SGMC	Events (19	9 Open)						
2017-06-WAH	Only show	events where	I am:	Y				
WA-2013-09-WAH		e <u>9 Amendme</u>						
Messages		e <u>6 Continuin</u>						
Welcome to IRBManager at Adventist HealthCare	You have	e <u>1 Deviation</u> e <u>1 Initial Rev</u> e <u>2 Reportabl</u>	view e					
My Docs & xForms	You have	e <u>19 Total Op</u>	<u>en</u> eve	nts				
0 Attachments	<u> </u>							
3 xForms	My Projec	ts (6 Active)						
	Project *	\$	<b>РІ</b> Ф	Title	* Expir	es 🕈	\$ \$	Reference Doc(s)
	2017-07- SGMC	Shady Grove Medical Center	Test PI, MD	A Randomized, Double Blind Controlled Factorial Clinical Trial of Edetate Disodium- Based Chelation and High-Dose Oral Vitamins and Minerals to Prevent Recurrent Cardiac Events in Diabetic Patients With a Prior Myocardial Infaction		8/2019	Closed to Enrollment	
	2017-07-	Grove Medical	PI,	Based Chelation and High-Dose Oral Vitamins and Minerals to Prevent Recurrent	02/13			
	2017-07- SGMC 2018-07-	Grove Medical Center Washington Adventist	PI, MD Test PI,	Based Chelation and High-Dose Oral Vitamins and Minerals to Prevent Recurrent Cardiac Events in Diabetic Patients With a Prior Myocardial Infaction	02/13		Enrollment Pending IRB	
	2017-07- SGMC 2018-07- WAH 2018-08-	Grove Medical Center Washington Adventist Hospital Washington Adventist	PI, MD Test PI, MD Test PI,	Based Chelation and High-Dose Oral Vitamins and Minerals to Prevent Recurrent Cardiac Events in Diabetic Patients With a Prior Myocardial Infaction EnSite Precision Observational Study	02/13	7/2020	Enrollment Pending IRB Review Pending IRB	
	2017-07- SGMC 2018-07- WAH 2018-08- WAH 2019- TEST-	Grove Medical Center Washington Adventist Hospital Washington Adventist Hospital Shady Grove Medical	PI, MD Test PI, MD Test PI, MD Test PI,	Based Chelation and High-Dose Oral Vitamins and Minerals to Prevent Recurrent Cardiac Events in Diabetic Patients With a Prior Myocardial Infaction EnSite Precision Observational Study CREST-H	02/13	7/2020 1/2019	Enrollment Pending IRB Review Pending IRB Review Pending IRB Pending IRB	

d) My Projects Table



## **Study Profile Information:**

2. Once you are on the study profile, you may begin submitting x-forms. To submit a x-form, go to the actions side bar and click 'Start xForm.' Afterwards, a list of available x-forms will populate. Choose the Site Closure Application.

Adventist	Home						Find Pro	ject (Ctrl+Q)	
HealthCare	Project 2019-TEST-	SGM	IC (IRE	3)			Help	Test's Settin	igs Sign o
	Project								
Actions	Proje	ect:	2019-1	TEST	Sponsor(s):	Duke Clinical Re	esearch Instit	ute (Primary)	
Send EMail	Committ	ee:	Advent	ist HealthCare IRB	Sponsor ID:				
tart xForm	Catego	ory:			Grants:	TEST			
Forms (0)	Departme	ent: (	Critical	Care					
Done	Agent Typ	es:	Device	• Drug	CRO:				
	TÌ	tle: I	Best Dr	rug/Device Study Ever	Year:	2018			
lecent Items	Expedited Catego	ory: (	6, 1B						
2019-TEST-SGMC 2017-07-SGMC	Commer	nts:							
2017-06-WAH	Project-Site								
WA-2013-09-WAH	Site(	(5): :	SGMC	- Shady Grove Medical Center and others	PI:	Test PI, MD			
lessages	Stat	us: I	Pendin	IRB Review	Additional:	N			
Welcome to IRBManager	Approv	val: p	February 13, 2018 for 11 months		Expiration:	R: February 11, 2019			
at Adventist			February 13, 2018		Other Expirations:				
HealthCare	ICF Version Da	te:	10/25/	2018	Number of				
My Docs & xForms					Subjects/Charts:				
0 Attachments	Commer	nts:							
2 xForms	▼Project-Site Contacts (2)								
	Name				* Role				•
	Elizabeth Carroll, MF	н			Sub-Investigator				
	Maria Halaguena				Research Coordinator				
	v ▼Events (3)								
	Event		Instance/UDF			Start +	Complete +	Last Mtg 🕈	
	Amendment	1					01/16/2019		
	Amendment	5					01/14/2019		
	Continuing Review	6					01/11/2019		
	Conunuing Review	0					01/11/2019		

Copyright @2000-2019 Tech Software, All Rights Reserved.



## Start a Site Closure Form:

3. Once you select the site closure form, the Study Header page will populate. The Study Header page contains information on the IRB study number, protocol site<sup>4</sup>, study expiration date, principal investigator, and agent type<sup>5</sup>. The creating user<sup>6</sup> will be the person who started the x-form.

	b) Collaborators Drop	Down	
Adventist HealthCare	A Collaborators Head		pe 1 of 6 Next
Site Closure Application Header	Ceating User Halaguena, Maria Email: Inhalague@adventisthealthcarry froatt	Ad	id Note View Audit
	IRB Study Number TWA-2013-09	Ad	ld Note View Audit
	Protocol Site Output WAH - Washington Adventist Hospital	Ad	id Note View Audit
	Study Name GraftMaster® RX Coronary Stent Graft System	Ad	id Note View Audit
	Study Expiration 7/12/2018 for 11 months - Expiration: 7/11/2019	Ad	id Note View Audit
	Principal Investigator PI, Test MD Email: mhalague@terpmail.umd.edu	Ad Phone:	id Note View Audit
	Organizational Entity WAH - Washington Adventist Hospital	Rename Ad	id Note View Audit
	Agent Type: HUD	Ad	Id Note View Audit
	Next Save for Later More .		

- a) The header drop down allows you to skip from one page to the next.
- b) The collaborators icon allows you to add others to view, edit, manage, and/or submit the form.
- c) You may also add notes to communicate with other collaborators or create notes for yourself.
- d) Click 'Next' to move to the next page of the form. If you wish to save and return to the form later, click 'Save for Later.'

### Site Closure Data Entry:

4. The next page will prompt you to enter the date of study closure and whether the study involved the use or access of PHI.

**Please note:** Questions on the x-forms are specifically conditioned based on your responses. In other words, certain questions will appear based on your answer(s) to a previous question(s). Furthermore, questions marked as required <u>cannot</u> be left unanswered. You will not be allowed to submit the form until you answer the required questions.

5. The following page will ask you for the study enrollment information at the site and study-wide since last IRB review.



Adventist HealthCare	A Collaborators Enrollment Numbers and Demographics	• Page	3 of 7	Next
Site Closure Application Enrollment Num	bers and Demographics			
	Number of Subjects/Records/Specimens Approved	Add	Note View Audit	
	100 aft f			
	Enrollment Numbers Study-Wide Drat	Add	Note View Audit	
	Number of subjects/records/specimens approved at this site: 100			
	Enter the Number of Subjects Consented & Enrolled Study-Wide Since Last IRB Review	w (Required)		
	Enter Total Number of Subjects Consented & Enrolled Study-Wide (Required)			
	Site Specific Enrollment Information	Add	Note View Audit	
	Number of Subjects Consented & Enrolled Since Last IRB Review (Required)			
	Total Number of Subjects Consented & Enrolled (Required)			
	Number of Subjects Consented Not Enrolled Since Last IRB Review (Required)			
	Total # of Subjects Consented Not Enrolled (Required)			
	Were any subjects removed from the study or withdrew early at this site? (Required) $\bigcirc$ Yes $\bigcirc$ No			
	Number of Subjects who Completed All Research Activities Since Last Review Rename			
	Total Number of Subjects who Completed All Research Activities (Required)			
	Previous Next Save for Later More >			

- a) The approved number of subjects/records/specimens is available for your reference.
- b) Enter the number of subjects consented and enrolled for the site and studywide since last IRB review.
- c) Enter the site-specific enrollment information.
- 6. Enter the race/ethnicity information for <u>only subjects that were consented and</u> <u>enrolled at the site since last IRB review.</u>

Adventist HealthCare	& Collab	orators	Racial & Ethnic Cate	gories	•	Page 4 of 7		Next
Site Closure Application Racial & Ethnic Cat	egories							
	Number of subject	ts consented and enrolled a	at the site since last IRB revi	ew			Add Note	
	17							
	Racial & Ethnic Ca	tegories Enrollment Inforn	nation				Add Note	
	In the table below,	insert the racial and ethnic ca	ategories of subjects consented	and enrolled at this :	site. Click <mark>'save'</mark> after ent	ering each row o	of data.	
	Please enter the rows in the table (Required)	racial and ethnic categorie should correspond to the	View Audit lata.					
	# of Subjects*	Gender*	Race*		Ethnicity*		Action	
		· · · · · · · · · · · · · · · · · · ·		٣		٣	Save	

- Previous Next Save for Later More +
- a) The number for subjects consented and enrolled at the site since the last IRB review is available for your convenience.
- b) Enter the subject's ID, gender, race, and ethnicity. If there were no subjects consented and enrolled since the last IRB review, enter '0' for the subject ID, and 'N/A' for the drop downs.
- c) You must save the information entered before adding another row of information.
- 7. For the following pages, you will answer questions about the study's safety and adverse events, protected health information/data management/record retention, and data management/research records.

### PI Sign-Off and Admin Pre-Review:

8. After you have entered all the required information, you may now submit the form or save for later. Once the form is submitted, it will go directly to the PI for sign-off.



9. The PI will receive the following email, as shown below, which will include information on the Site Closure and a link to the Site Closure Form.



IRB@adventisthealthcare.com mhalague@terpmail.umd.edu
Site Closure for TWA-2013-09 Requires Signature

12:48 AM

 $\sim$ 

Dear Test PI, MD,

Maria Halaguena has submitted a site closure for TWA-2013-09-GraftMaster® RX Coronary Stent Graft System.

Click here to review and sign-off on the submission. Site Closure Application

For additional questions, please contact the IRB Office at 301-315-3400.

10. If the PI has suggested comments/modifications to the site closure form prior to IRB submission, you will receive the following email, as shown below. The site closure form will go back to data entry and you may edit the form accordingly.

IRB@adventisthealthcare.com	mhalague@adventisthealthcare.com	12:51 AM
PI Requested Changes to Site Cl	osure for TWA-2013-09	~

Dear Maria Halaguena,

Test PI, MD has reviewed the site closure for TWA-2013-09-GraftMaster<sup>®</sup> RX Coronary Stent Graft System and is requesting changes before it can be submitted to the IRB.

PI requested changes:

test

Click here to access the form and make the changes. Site Closure Application

For additional questions, please contact the IRB Office at 301-315-3400.

11. After you have finished making the revisions, the form will go back to the PI for sign off.

**Please note:** Every time a change is made to the study documents, the PI must sign off afterwards.

12. The IRB Office will review the site closure form and if there are any changes requested, you will receive the following email.



	IRB@adventisthealthcare.com m	nalague@terpmail.umd.edu; mhalague@adventisthealthcare.com 🝷	12:59 AM
	IRB Admin Requesting Changes to S	ite Closure for TWA-2013-09	~
IRB Stu	dy Number: TWA-2013-09		
Study 1	ïtle: GraftMaster® RX Coronary Stent Graft	System	
Dear Te	est PI, MD,		
The IRE	Office has administratively reviewed the a	bove referenced submission for consistency and completene	ss.
Please	address the following questions:		
test			
Click he	ere to access the form. Site Closure Applicat	tion Rename	
	rm is open for edits. Please respond to the contacted at <u>IRB@adventisthealthcare.com</u>	se concerns and include any revised documentation in the for or 301-315-3400 with any questions.	m. The IRB Office
Thank	you.		

13. To make the changes requested by the IRB Office, click on the blue form link and you will be directed to the x-form. The IRB Office will utilize the notes feature to communicate the required changes to the research study teams, which will make it easier to identify the required changes on the x-form. You may also use the notes feature to communicate with your collaborators by keeping them internal.

Adventist HealthCare	æ	Collaborators	Protected Health Information/Data M	anagement/Record R 🔻	Page	of 7	Next	
Site Closure Application Protected Health Info	rmation/Dat	ta Management/Record Reten	tion					
		ll you keep the PHI or link (ide (v) (Required)	entifying code) to the PHI ident	ifiers? (State timeframe in mor	nths/years Add !	ote View Audit		
		Entered: 03/20/19 By: Hala test	guena, Maria <b>Internal:</b> No		<i>₫</i> <b>9</b> , 1	٢		
	testing				*			
					//			
V	Who will hav	re access to PHI identifiers col	lected for this research study?	(Required)		ote View Audit		
	testing				*			
Ľ								
F	Please provi	de your plan to ensure that PH	II will not be improperly disclos	ed. (Required)	Add I	ote View Audit		
	test				**			
				Rename	1			

Previous Next Save for Later More +

**Please note:** You cannot submit the form until the changes requested by the IRB Office have been made.

- 14. After you have made the changes requested by the IRB Office, the form will go to the PI for sign off.
- 15. If no additional changes are requested by the PI and IRB Office, the site closure form is ready to be reviewed by the IRB.



### **IRB Review:**

### **Expedited Review**

16. If the site closure is reviewed via expedited review, the study team should receive an acknowledgement letter within 4-5 business days. The acknowledgement letter will be sent to the PI and creating user via email, as shown below.

T		nalague@terpmail.umd.edu; mhalague@adventisthealthcare.com  +	01	11:47 AM
	TWA-2013-09: Study Closure			~
PDF J	TWA-2013-09 Acknowledgement Letter dated Mar 80 KB	2019.pdf _		

IRB Study Number: TWA-2013-09

Study Title: GraftMaster® RX Coronary Stent Graft System

Dear Test PI, MD,

Attached is the study closure acknowledgement letter for the above referenced study. This protocol is now closed and no further study activities are authorized, including long-term follow-up, long-term data collection, and data analysis.

Please contact the IRB office at IRB@adventisthealthcare.com or (301) 315-3400 with any questions.

Thank you.

17. If the site closure receives a determination other than a full-approval, you will receive an email, as shown below, prompting you to make revisions to the form. To make the changes, click on the blue form link. After you have made revisions, the form will go to the PI for sign-off.



 IRB@adventisthealthcare.com
 mhalague@terpmail.umd.edu; mhalague@adventisthealthcare.com
 Wed 9:47 AM

 Study TWA-2013-09 Site Closure Requires Changes
 v

IRB Study Number: TWA-2013-09

Study Title: GraftMaster® RX Coronary Stent Graft System

Dear Test PI, MD,

The IRB has reviewed the site closure documents for the above referenced study via expedited review and determined that modifications are needed. Please address the following questions:

test

Please click the form link to access the form and make changes. Site Closure Application

Thank you.

### **Referral to Full-Board**

18. If the site closure is referred to full-board review, you will receive the email, as shown below, informing you of the referral.

	IRB@adventisthealthcare.com	mhalague@terpmail.umd.edu; mhalague@adventisthealthcare.com 👻	7:41 PM
1	Study 2018-07 Referred to Full-B	oard	~

IRB Study Number: 2018-07

Study Name: EnSite Precision Observational Study

Dear Test PI, MD,

2018-07-EnSite Precision Observational Study was referred for full-board review. Please contact the IRB Office at IRB@adventisthealthcare.com or 301-315-3400 with any questions.

Thank you.

#### **Full-Board**

19. After the convened IRB meeting, the PI and creating user will receive an email containing the determination letter and informed consent form (if applicable) within two days of the IRB meeting.



- 20. If the IRB has determined that modifications are needed to the site closure form, the IRB Office will send an email to the PI and creating user of the changes requested. The determination letter will be available in both a pdf and word copy for your convenience. The form will then go back to data entry and PI sign off.
- 21. To view the determination letter and stamped informed consent form within IRBManager, go to the study profile and click on the 'Site Closure event'. On the 'actions side bar', go to 'attachments' and then 'generated docs'.

#### **Principal Investigator Guidance**

1. You will receive an email from <u>IRB@adventisthealthcare.com</u> informing you an xform has been completed by a research staff member. The email will contain a link to the site closure form.

I	IRB@adventisthealthcare.com mhalague@terpmail.umd.edu Site Closure for TWA-2013-09 Requires Signature	1:02 AM
Dear Tes	st PI, MD,	

Maria Halaguena has submitted a site closure for TWA-2013-09-GraftMaster® RX Coronary Stent Graft System.

Click here to review and sign-off on the submission. Site Closure Application

For additional questions, please contact the IRB Office at 301-315-3400.

- 2. The blue form link will take you directly to the x-form for your signature. You can see the information entered by the creating user such as the specific changes to the research, rationale and justification for the proposed changes, attachments, etc.
- If you agree with the information put forth in the submission and attest to the closure of the study, you will electronically sign-off on the document by inputting your IRBManager password.



Adventist HealthCare	Collaborators PI Attestation and Signature v Page 1 of 1	Next
Site Closure Application	n PI Attestation and Signature	
	Is this site closure ready to be sent to the IRB? (Required) View Audit	
	●Yes ○No	
	I have followed all applicable policies and procedures of Adventist HealthCare and federal, state and local laws view Audit regarding the protection of human subjects in research, including, but not limited to, the following:	
	<ul> <li>The research is/was performed as approved by the IRB under the direction of the Principal Investigator by appropriately trained and qualified personnel;</li> </ul>	
	<ul> <li>Unanticipated problems were promptly reported to the IRB, as well as any other information necessary for appropriate oversight of the research;</li> </ul>	
	<ul> <li>Research-related records and source documents will be maintained in a manner that documents the validity of the study and integrity of the data collected, while protecting the confidentiality of the data and privacy of participants;</li> </ul>	
	· IRB approval or exemption will be obtained before initiating any new research activities involving human subjects; and	
	<ul> <li>All co-investigators, research staff, and employees assisting in the conduct of the research will be informed of their obligations in meeting the above commitments.</li> </ul>	
	I verify that the information provided on this Form is accurate and complete.	
	By entering your password in the space below, you acknowledge this site closure a Rename on and are electronically signing this form.	
	(Required) To sign, enter password for mhalague@terpmail.umd.edu	
	Previous) Next Save for Later More •	

4. If you would like to request changes to the submission, you can indicate the changes you are requesting in the text box. These comments will go directly to the creating user.

00011			
Adventist HealthCare	Scollaborators PI Attestation and Signature •	Page 1 of 1	Next
Site Closure Application	PI Attestation and Signature		
	Is this site closure ready to be sent to the IRB? (Required)	View Audit	
	⊖Yes ●No		
	Indicate the changes you are requesting. (Required)	View Audit	
	test	These comments will go directly to the form submitter.	
	Previous Next Save for Later More •		

5. Please be aware that your signature is required every time a change is made to the study documents. Any changes made to the study documents will be highlighted in yellow.



## Terminology for IRBManager:

- <sup>1</sup>X-forms: online version of the currently existing submission documents with slight modifications
- <sup>2</sup>Projects: research studies
- <sup>3</sup>Study Events/Events: actions or reviews for research studies. Examples include amendments, continuing review, and reportable event
- <sup>4</sup>Protocol site output: where the study will primarily take place. There may be more than one site listed.
- <sup>5</sup>Agent type: description of the nature of the study or the investigational aspect of the study (e.g., observational, specimen review, drug, device, etc.)
- <sup>6</sup>Creating user: the study staff member who started the x-form data entry